Allergan (AGN) ramps up its propaganda efforts in its battle to stay out the clutches of Valeant (VRX), saying that it expects EPS to increase 20-25% in 2015 and at an annual compound rate of 20% over five years.
The company also forecasts "double-digit revenue growth" next year and over the coming five years.
Meanwhile, Allergan has received over 500 letters from physician customers, patient advocacy groups and medical associations expressing support for the company following its rejection of Valeant's bid.
Physicians have what Allergan describes as "grave concerns" about Valeant's proposal to slash Allergan's R&D expenditure by $1B a year. (PR)